Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial

BACKGROUND: Few controlled clinical trials exist to support oral combination therapy in pulmonary arterial hypertension (PAH). METHODS: Patients with PAH (idiopathic [IPAH] or associated with connective tissue disease [APAH-CTD]) taking bosentan (62.5 or 125 mg twice daily at a stable dose for ≥3 mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Vizza, Carmine Dario, Jansa, Pavel, Teal, Simon, Dombi, Theresa, Zhou, Duo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586020/
https://www.ncbi.nlm.nih.gov/pubmed/28874133
http://dx.doi.org/10.1186/s12872-017-0674-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586020/
https://www.ncbi.nlm.nih.gov/pubmed/28874133
http://dx.doi.org/10.1186/s12872-017-0674-3

Ejemplares similares